Ruanyun Edai Technology Inc. (RYET) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, RYET scores 35 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the Fundamental Cash Engine scores 8 of 20 (ROIC 0%; FCF yield 0%), indicating that the business is not currently converting capital into returns or free cash flow. The Whale 13F Flow pillar scores 7 of 20 (institutional accumulation and options positioning), suggesting limited institutional support in the source data. Insider Conviction scores 5 of 20 (SEC Form 4 and Congressional PTR cluster flow), the weakest pillar, implying little insider signaling of confidence. Macro Regime Fit scores 7 of 20 (Beta 1.0; sector sensitivity), meaning the stock tracks broad market movements without a clear defensive offset. Forensic Balance Sheet scores 8 of 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), reflecting weak financial-health signals on the Piotroski scale despite a middling Altman reading.

For a prospective investor evaluating the stock today, the practical implication is that the upside case rests on a turnaround that the reported cash flows do not yet demonstrate. Valuation tradeoffs are difficult to assess because earnings-based multiples are unavailable, and the operating margin of -60% per the market data section means losses are large relative to revenue. Any thesis would need to be built on catalysts and survival of the balance sheet rather than current earnings power.

Ruanyun Edai Technology Inc. is a NASDAQ-listed issuer in the Technology sector, operating within the Computer Software: Prepackaged Software industry, per the profile section. Per the recent news wire, the company's subsidiary has pursued marketing arrangements, including a Taiwan marketing deal for a Chinese learning platform and a licensing arrangement for a healthcare-related AI product. Revenue figures are reported in the SEC financials, but the source data does not describe the product mix, customer base, or detailed revenue model. Gross margin is reported at 25.2% per the market data section.

Per the SEC financials, operating losses widened substantially in FY 2025 to $-7.3M from $-0.5M in FY 2024, and free cash flow turned to $-9.2M. Per the market data section, ROIC is 0%, the net margin is -60%, and the operating margin is -60%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash and debt balances are not available in the source data, so liquidity runway cannot be directly assessed.

The recent news wire contains six items, all tagged with a YELLOW light and MARKET WIRE impact label. A Nasdaq minimum bid price deficiency notice is reported, which is a material risk watch item given the $0.7 price. Other items cover a Taiwan market development agreement tied to a subsidiary (HanLink), a Taiwan marketing deal for a Chinese learning platform, a seasonal returns chart, a mention in an after-market movers list, and an exclusive Cogni AI license for entry into Malaysian healthcare through BioNexus Gene Lab. Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded. The news items are largely promotional in nature and do not include quantified financial impact.

• What are the cash and debt balances, and how many months of runway exist at the FY 2025 free cash flow burn rate of $-9.2M?
• What is the outcome of the Nasdaq minimum bid price deficiency notice, and what compliance timeline applies?
• What share of FY 2025 revenue derives from the newly announced Taiwan and Malaysian arrangements versus existing operations?
• Why did operating losses widen from $-0.5M in FY 2024 to $-7.3M in FY 2025, and is the trend expected to continue?
• What explains the gap between a 25.2% gross margin and a -60% operating margin, in terms of operating expense composition?